Private Capital Group’s Fortress Biotech 9.375% Series A Preferred Stock FBIOP Stock Holding History

Private Capital Group’s Portfolio FBIOP Stock Details FBIOP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-135	Closed	-$3K	–	1954
2022 Q1	$3K	Hold	135	–	–	﹤0.01%	1670
2021 Q4	$4K	Hold	135	–	–	﹤0.01%	1607
2021 Q3	$4K	Hold	135	–	–	﹤0.01%	1644
2021 Q2	$4K	Hold	135	–	–	﹤0.01%	1630
2021 Q1	$3K	Hold	135	–	–	﹤0.01%	1655
2020 Q4	$3K	Hold	135	–	–	﹤0.01%	1666
2020 Q3	$3K	Hold	135	–	–	﹤0.01%	1611
2020 Q2	$2K	Buy	135 +62	+85%	+$1.13K	﹤0.01%	1684
2020 Q1	$1K	Buy	+73	New	+$1.41K	﹤0.01%	1792

Other funds holding FBIOP

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Private Capital Group's FBIOP Position: Q2 2022 in Review

Private Capital Group sold out of Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) in Q2 2022, closing a stake of 135 shares — an estimated $3K sold.

Private Capital Group first reported a position in FBIOP in Q1 2020 and held it in 9 quarters. The position peaked at $4K in Q4 2021. 1 fund tracked by Wall St. Rank holds FBIOP as of Q2 2022.

Private Capital Group reported no remaining Fortress Biotech 9.375% Series A Preferred Stock position as of Q2 2022 after selling out during the quarter.
Private Capital Group sold 135 Fortress Biotech 9.375% Series A Preferred Stock shares in Q2 2022, an estimated $3K.
Private Capital Group first reported a position in Fortress Biotech 9.375% Series A Preferred Stock in Q1 2020 and held it in 9 quarters.
Private Capital Group's Fortress Biotech 9.375% Series A Preferred Stock position peaked at $4K in Q4 2021.
1 fund tracked by Wall St. Rank held Fortress Biotech 9.375% Series A Preferred Stock as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.